deferoxamine has been researched along with Neoplasms in 55 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine B is an outstanding molecule which has been widely studied in the past decade for its ability to bind iron and many other metal ions." | 2.72 | Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. ( Bellotti, D; Remelli, M, 2021) |
| "The importance of iron and copper in cancer biology has been well established." | 2.43 | Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. ( Kalinowski, DS; Lovejoy, DB; Richardson, DR; Wong, J; Yu, Y, 2006) |
| "DLD-1 tumors exhibited similar pharmacokinetics, but tumor uptake and T:M ratios were reduced ∼2-fold in comparison to NCI-H460 at all time points." | 1.40 | Immuno-PET imaging of tumor endothelial marker 8 (TEM8). ( Bhadrasetty, V; Chaudhary, A; Choyke, P; Coble, V; Elbuluk, O; Griffiths, GL; Histed, S; Jagoda, EM; Kuo, F; Lane, K; Paik, CH; St Croix, B; Szajek, LP; Szot, C; Vasalatiy, O; Williams, MR; Wong, K; Wu, H; Xu, B, 2014) |
| "Given that most solid human tumors have focal hypoxic areas and that AM functions as a mitogen, angiogenic factor, and apoptosis-survival factor, our findings implicate the HIF-1/AM link as a possible promotion mechanism of carcinogenesis." | 1.31 | Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. ( An, WG; Cuttitta, F; Garayoa, M; Gassmann, M; Johnson, R; Lee, S; Martínez, A; Montuenga, LM; Neckers, L; Pío, R; Ryan, H; Trepel, J, 2000) |
| "We tested non-hematopoietic human tumors for in vitro sensitivity to either a pair of synergistic IgG antitransferrin (Tf) receptor monoclonal antibodies (MAbs), deferoxamine (DFO) or the combination thereof." | 1.29 | Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro. ( Kemp, JD; Kovar, J; Naumann, PW; Stewart, BC, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (14.55) | 18.7374 |
| 1990's | 10 (18.18) | 18.2507 |
| 2000's | 14 (25.45) | 29.6817 |
| 2010's | 14 (25.45) | 24.3611 |
| 2020's | 9 (16.36) | 2.80 |
| Authors | Studies |
|---|---|
| Serda, M | 1 |
| Kalinowski, DS | 3 |
| Mrozek-Wilczkiewicz, A | 1 |
| Musiol, R | 1 |
| Szurko, A | 1 |
| Ratuszna, A | 1 |
| Pantarat, N | 1 |
| Kovacevic, Z | 3 |
| Merlot, AM | 1 |
| Richardson, DR | 9 |
| Polanski, J | 1 |
| Wu, Q | 1 |
| Young, B | 1 |
| Wang, Y | 1 |
| Davidoff, AM | 1 |
| Rankovic, Z | 1 |
| Yang, J | 1 |
| Mielke, N | 1 |
| Johnson, S | 1 |
| Bahl, A | 1 |
| Fadladdin, YAJ | 1 |
| Xue, M | 1 |
| Zhang, X | 1 |
| Chen, J | 1 |
| Liu, F | 1 |
| Xu, J | 1 |
| Xie, J | 1 |
| Yang, Y | 1 |
| Yu, W | 1 |
| Qiu, H | 1 |
| Xue, J | 1 |
| Jiang, J | 1 |
| Liu, Y | 2 |
| Shallom, SJ | 1 |
| Zelazny, AM | 1 |
| Giri, AR | 1 |
| Kaur, N | 1 |
| Yarrarapu, SNS | 1 |
| Rottman Pietrzak, KA | 1 |
| Santos, C | 1 |
| Lowman, PE | 1 |
| Niaz, S | 1 |
| Franco, PM | 1 |
| Sanghavi, DK | 1 |
| Zhu, D | 1 |
| Liang, R | 1 |
| Li, Z | 2 |
| Cheng, L | 1 |
| Ren, J | 1 |
| Guo, Y | 2 |
| Wang, M | 1 |
| Chai, H | 1 |
| Niu, Q | 1 |
| Yang, S | 1 |
| Bai, J | 1 |
| Yu, H | 1 |
| Zhang, H | 1 |
| Qin, X | 1 |
| Sahrakorpi, N | 1 |
| Engberg, E | 1 |
| Stach-Lempinen, B | 1 |
| Tammelin, TH | 1 |
| Kulmala, J | 1 |
| Roine, RP | 1 |
| Koivusalo, SB | 1 |
| Cheng, W | 1 |
| Pang, H | 1 |
| Campen, MJ | 1 |
| Zhang, J | 2 |
| Li, Y | 1 |
| Gao, J | 1 |
| Ren, D | 1 |
| Ji, X | 1 |
| Rothman, N | 1 |
| Lan, Q | 1 |
| Zheng, Y | 1 |
| Leng, S | 1 |
| Hu, Z | 1 |
| Tang, J | 1 |
| Dong, Q | 1 |
| Song, N | 1 |
| Qin, N | 1 |
| Chen, C | 1 |
| Sun, X | 1 |
| Easton, J | 1 |
| Mulder, H | 1 |
| Plyler, E | 1 |
| Neale, G | 1 |
| Walker, E | 1 |
| Li, Q | 1 |
| Ma, X | 1 |
| Chen, X | 1 |
| Huang, IC | 1 |
| Yasui, Y | 1 |
| Ness, KK | 1 |
| Hudson, MM | 1 |
| Robison, LL | 1 |
| Wang, Z | 1 |
| Subota, A | 1 |
| Spotswood, N | 1 |
| Roach, M | 1 |
| Goodarzi, Z | 1 |
| Holroyd-Leduc, J | 1 |
| Park, EA | 1 |
| Graves, SA | 1 |
| Menda, Y | 1 |
| Yue, TTC | 1 |
| Ge, Y | 1 |
| Aprile, FA | 1 |
| Ma, MT | 1 |
| Pham, TT | 1 |
| Long, NJ | 1 |
| Harada, T | 1 |
| Hirose, K | 1 |
| Wada, Y | 1 |
| Sato, M | 1 |
| Ichise, K | 1 |
| Aoki, M | 1 |
| Kato, T | 1 |
| Takeda, K | 1 |
| Takai, Y | 1 |
| Merkul, E | 1 |
| Muns, JA | 1 |
| Sijbrandi, NJ | 1 |
| Houthoff, HJ | 1 |
| Nijmeijer, B | 1 |
| van Rheenen, G | 1 |
| Reedijk, J | 1 |
| van Dongen, GAMS | 1 |
| Menghini, S | 1 |
| Ho, PS | 1 |
| Gwisai, T | 1 |
| Schuerle, S | 1 |
| Kono, Y | 1 |
| Utsunomiya, K | 1 |
| Kan, N | 1 |
| Matsumoto, Y | 1 |
| Sakata, Y | 1 |
| Ohira, Y | 1 |
| Satoh, H | 1 |
| Koda, K | 1 |
| Matsuura, T | 1 |
| Tanigawa, N | 1 |
| Sandoval-Acuña, C | 1 |
| Torrealba, N | 1 |
| Tomkova, V | 1 |
| Jadhav, SB | 1 |
| Blazkova, K | 1 |
| Merta, L | 1 |
| Lettlova, S | 1 |
| Adamcová, MK | 1 |
| Rosel, D | 1 |
| Brábek, J | 1 |
| Neuzil, J | 1 |
| Stursa, J | 1 |
| Werner, L | 1 |
| Truksa, J | 1 |
| Bellotti, D | 1 |
| Remelli, M | 1 |
| Morrison, RA | 1 |
| Rybak-Smith, MJ | 1 |
| Thompson, JM | 1 |
| Thiebaut, B | 1 |
| Hill, MA | 1 |
| Townley, HE | 1 |
| Heskamp, S | 1 |
| Raavé, R | 1 |
| Boerman, O | 1 |
| Rijpkema, M | 1 |
| Goncalves, V | 1 |
| Denat, F | 1 |
| Hajdu, I | 1 |
| Makhlouf, A | 1 |
| Solomon, VR | 1 |
| Michel, D | 1 |
| Al-Dulaymi, M | 1 |
| Wasan, KM | 1 |
| Fonge, H | 1 |
| Badea, I | 1 |
| Bedford, MR | 1 |
| Ford, SJ | 1 |
| Horniblow, RD | 1 |
| Iqbal, TH | 1 |
| Tselepis, C | 1 |
| Hoffer, PB | 1 |
| Samuel, A | 1 |
| Bushberg, JT | 1 |
| Thakur, M | 1 |
| Sahni, S | 1 |
| Bae, DH | 1 |
| Lane, DJ | 1 |
| Jansson, PJ | 2 |
| Kuo, F | 1 |
| Histed, S | 1 |
| Xu, B | 1 |
| Bhadrasetty, V | 1 |
| Szajek, LP | 1 |
| Williams, MR | 1 |
| Wong, K | 1 |
| Wu, H | 1 |
| Lane, K | 1 |
| Coble, V | 1 |
| Vasalatiy, O | 1 |
| Griffiths, GL | 1 |
| Paik, CH | 1 |
| Elbuluk, O | 1 |
| Szot, C | 1 |
| Chaudhary, A | 1 |
| St Croix, B | 1 |
| Choyke, P | 1 |
| Jagoda, EM | 1 |
| Gutierrez, E | 1 |
| Wilks, MQ | 1 |
| Normandin, MD | 1 |
| Yuan, H | 1 |
| Cho, H | 1 |
| Herisson, F | 1 |
| Ayata, C | 1 |
| Wooten, DW | 1 |
| El Fakhri, G | 1 |
| Josephson, L | 1 |
| Yalcintepe, L | 1 |
| Halis, E | 1 |
| Wang, G | 1 |
| Shen, G | 1 |
| Yin, T | 1 |
| Hervouet, E | 1 |
| Cízková, A | 1 |
| Demont, J | 1 |
| Vojtísková, A | 1 |
| Pecina, P | 1 |
| Franssen-van Hal, NL | 1 |
| Keijer, J | 1 |
| Simonnet, H | 1 |
| Ivánek, R | 1 |
| Kmoch, S | 1 |
| Godinot, C | 1 |
| Houstek, J | 1 |
| Ruggiero, A | 1 |
| Holland, JP | 2 |
| Lewis, JS | 3 |
| Grimm, J | 1 |
| Yu, Y | 2 |
| Heneweer, C | 1 |
| Divilov, V | 1 |
| Carlin, S | 1 |
| Lovejoy, DB | 2 |
| Linden, T | 1 |
| Wenger, RH | 1 |
| Mathias, CJ | 1 |
| Lewis, MR | 1 |
| Reichert, DE | 1 |
| Laforest, R | 1 |
| Sharp, TL | 1 |
| Yang, ZF | 1 |
| Waters, DJ | 1 |
| Snyder, PW | 1 |
| Low, PS | 1 |
| Welch, MJ | 1 |
| Green, MA | 1 |
| Le, NT | 1 |
| Um, JH | 1 |
| Kang, CD | 1 |
| Bae, JH | 1 |
| Shin, GG | 1 |
| Kim, DW | 2 |
| Chung, BS | 1 |
| Kim, SH | 1 |
| Buss, JL | 1 |
| Greene, BT | 1 |
| Turner, J | 1 |
| Torti, FM | 1 |
| Torti, SV | 1 |
| Ranney, D | 1 |
| Antich, P | 1 |
| Dadey, E | 1 |
| Mason, R | 1 |
| Kulkarni, P | 1 |
| Singh, O | 1 |
| Chen, H | 1 |
| Constantanescu, A | 1 |
| Parkey, R | 1 |
| Sliskovic, I | 1 |
| Mutus, B | 1 |
| Weinberg, ED | 1 |
| Wong, J | 1 |
| Cohen, AR | 1 |
| Wesbey, GE | 1 |
| Engelstad, BL | 1 |
| Brasch, RC | 1 |
| Koizumi, K | 1 |
| Tonami, N | 1 |
| Hisada, K | 1 |
| Morini, PL | 1 |
| Bianchi, MA | 1 |
| Borsotti, M | 1 |
| Hershko, C | 1 |
| Herbert, V | 1 |
| Shaw, S | 1 |
| Jayatilleke, E | 1 |
| Stopler-Kasdan, T | 1 |
| Voest, EE | 1 |
| Neijt, JP | 1 |
| Keunen, JE | 1 |
| Dekker, AW | 1 |
| van Asbeck, BS | 1 |
| Nortier, JW | 1 |
| Ros, FE | 1 |
| Marx, JJ | 1 |
| Kovar, J | 1 |
| Naumann, PW | 1 |
| Stewart, BC | 1 |
| Kemp, JD | 1 |
| Donfrancesco, A | 1 |
| Deb, G | 1 |
| De Sio, L | 1 |
| Cozza, R | 1 |
| Castellano, A | 1 |
| Kling, PJ | 1 |
| Dragsten, PR | 1 |
| Roberts, RA | 1 |
| Dos Santos, B | 1 |
| Brooks, DJ | 1 |
| Hedlund, BE | 1 |
| Taetle, R | 1 |
| Meijs, WE | 1 |
| Haisma, HJ | 1 |
| Klok, RP | 1 |
| van Gog, FB | 1 |
| Kievit, E | 1 |
| Pinedo, HM | 1 |
| Herscheid, JD | 1 |
| Milnes, K | 1 |
| Chiou, TJ | 1 |
| Chou, YT | 1 |
| Tzeng, WF | 1 |
| Garayoa, M | 1 |
| Martínez, A | 1 |
| Lee, S | 1 |
| Pío, R | 1 |
| An, WG | 1 |
| Neckers, L | 1 |
| Trepel, J | 1 |
| Montuenga, LM | 1 |
| Ryan, H | 1 |
| Johnson, R | 1 |
| Gassmann, M | 1 |
| Cuttitta, F | 1 |
| Littleton, RJ | 1 |
| Baker, GM | 1 |
| Soomro, IN | 1 |
| Adams, RL | 1 |
| Whimster, WF | 1 |
| Gambari, R | 1 |
| Barbieri, R | 1 |
| Piva, R | 1 |
| Viola, L | 1 |
| Castagnoli, A | 1 |
| Del Senno, L | 1 |
| Furukawa, T | 1 |
| Endo, K | 1 |
| Ohmomo, Y | 1 |
| Sakahara, H | 1 |
| Koizumi, M | 1 |
| Nakashima, T | 1 |
| Fukunaga, M | 1 |
| Morita, R | 1 |
| Hirai, H | 1 |
| Yokoyama, A | 1 |
| Brockman, RW | 1 |
| Desenne, JJ | 1 |
| Layrisse, M | 1 |
15 reviews available for deferoxamine and Neoplasms
| Article | Year |
|---|---|
Recent Advances with KDM4 Inhibitors and Potential Applications.
Topics: Enzyme Inhibitors; Histone Demethylases; Humans; Jumonji Domain-Containing Histone Demethylases; Neo | 2022 |
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas | 2022 |
Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator.
Topics: Animals; Antineoplastic Agents; Chelating Agents; Chemistry, Pharmaceutical; COVID-19 Drug Treatment | 2021 |
Topics: Animals; Chelating Agents; Deferoxamine; Drug Delivery Systems; Drug Discovery; Humans; Immunoconjug | 2017 |
Iron chelation in the treatment of cancer: a new role for deferasirox?
Topics: Animals; Antineoplastic Agents; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chel | 2013 |
Therapeutic potential of iron chelators in cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Deferoxamine; Humans; Iron; Iron Chelating Agents; Isoni | 2002 |
Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators.
Topics: Animals; Antineoplastic Agents; Deferoxamine; Humans; Hydrazones; Iron; Iron Chelating Agents; Neopl | 2003 |
Iron chelators in cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chelation Therapy; D | 2004 |
Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
Topics: Animals; Bacterial Infections; Deferoxamine; Free Radicals; Humans; Iron; Iron Chelating Agents; Iro | 2006 |
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
Topics: Antineoplastic Agents; Chelating Agents; Deferoxamine; Humans; Neoplasms; Pyridines; Structure-Activ | 2006 |
Pediatric iron overload.
Topics: Chelating Agents; Child; Deferoxamine; Humans; Iron; Iron Overload; Neoplasms | 2007 |
Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators.
Topics: Animals; Brain; Cell Division; Chelation Therapy; Deferoxamine; Graft Rejection; Heart; Humans; Iron | 1994 |
Most free-radical injury is iron-related: it is promoted by iron, hemin, holoferritin and vitamin C, and inhibited by desferoxamine and apoferritin.
Topics: Animals; Anticarcinogenic Agents; Apoferritins; Ascorbic Acid; Carcinogens; Deferoxamine; Diet; Ferr | 1994 |
Role of deferoxamine in tumor therapy.
Topics: Antineoplastic Agents; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Neoplasms; Neur | 1996 |
Biochemical aspects of drug combinations.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Bleomycin; Camptothecin; Cell Division; Cytarabin | 1974 |
2 trials available for deferoxamine and Neoplasms
| Article | Year |
|---|---|
Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Citrates; Citric Acid; Deferoxamine; Do | 1993 |
Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy.
Topics: Adult; Antibodies, Monoclonal; Blood Cell Count; Carcinoma, Hepatocellular; Cell Hypoxia; Deferoxami | 1996 |
38 other studies available for deferoxamine and Neoplasms
| Article | Year |
|---|---|
Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deferoxamine; Humans; Iron; Iron Chelat | 2012 |
Site-Specific
Topics: Animals; Cell Line, Tumor; Chelating Agents; Deferoxamine; Gallium Radioisotopes; Immunoconjugates; | 2023 |
YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells.
Topics: Antineoplastic Agents; Boron Neutron Capture Therapy; Cell Hypoxia; Cell Line, Tumor; Cell Survival; | 2020 |
An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the Pt
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Coordination Complexes; Deferoxamine; Humans; Imm | 2021 |
Topics: Cell Line, Tumor; Cell Survival; Deferoxamine; Humans; Iron Chelating Agents; Magnetospirillum; Neop | 2021 |
A comparison of HER2/neu accumulations of Ga-67-labeled anti-HER2 antibody with chemically and site-specifically conjugated bifunctional chelators.
Topics: Animals; Antibodies, Monoclonal; CHO Cells; Cricetulus; Deferoxamine; Female; Gallium Radioisotopes; | 2021 |
Targeting Mitochondrial Iron Metabolism Suppresses Tumor Growth and Metastasis by Inducing Mitochondrial Dysfunction and Mitophagy.
Topics: Animals; Carcinogenesis; Cell Death; Cell Movement; Cell Proliferation; Deferoxamine; Heme; Humans; | 2021 |
Efficacy of radiosensitizing doped titania nanoparticles under hypoxia and preparation of an embolic microparticle.
Topics: Cell Line, Tumor; Cobalt; Deferoxamine; Embolization, Therapeutic; Gadolinium; Humans; Nanoparticles | 2017 |
A
Topics: Animals; Cell Survival; Deferoxamine; Gene Expression Regulation; Gene Transfer Techniques; Genetic | 2018 |
Effect of desferoxamine on tissue and tumor retention of gallium-67: concise communication.
Topics: Animals; Chelating Agents; Deferoxamine; Gallium Radioisotopes; Male; Mice; Neoplasms; Tissue Distri | 1979 |
The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells.
Topics: Autophagy; Cell Cycle Proteins; Cell Line, Tumor; Copper; Deferoxamine; eIF-2 Kinase; Endoplasmic Re | 2014 |
Immuno-PET imaging of tumor endothelial marker 8 (TEM8).
Topics: Animals; Antibodies, Monoclonal, Humanized; Blotting, Western; Deferoxamine; Female; Humans; Immunop | 2014 |
The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity.
Topics: Acetylcysteine; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Survival; Copper; Deferoxam | 2014 |
Imaging PEG-like nanoprobes in tumor, transient ischemia, and inflammatory disease models.
Topics: Animals; Brain; Brain Ischemia; Carbocyanines; Cell Line, Tumor; Deferoxamine; Female; Inflammation; | 2015 |
Modulation of iron metabolism by iron chelation regulates intracellular calcium and increases sensitivity to doxorubicin.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Calcium Signaling; Cell Survival; Cytoplasm; Deferoxamine | 2016 |
In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow.
Topics: Animals; Apoptosis; Bone Marrow Cells; Cell Proliferation; Deferoxamine; Intercellular Adhesion Mole | 2017 |
HIF and reactive oxygen species regulate oxidative phosphorylation in cancer.
Topics: Aryl Hydrocarbon Receptor Nuclear Translocator; Carrier Proteins; Cobalt; Cytoskeletal Proteins; Def | 2008 |
Cerenkov luminescence imaging of medical isotopes.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Beta Particles; Deferoxamine; Diagnostic Imaging; | 2010 |
Chelators to the rescue: different horses for different courses!
Topics: Aldehydes; Animals; Deferoxamine; Humans; Hydrazones; Iron Chelating Agents; Iron Overload; Isoniazi | 2011 |
Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system.
Topics: Animals; Autoradiography; Deferoxamine; Drug Stability; Humans; Image Processing, Computer-Assisted; | 2011 |
Iron chelation, angiogenesis and tumor therapy.
Topics: Antineoplastic Agents; Chelation Therapy; Deferoxamine; Endothelium, Vascular; Humans; Iron; Iron Ch | 2003 |
Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals.
Topics: Animals; Autoradiography; Carrier Proteins; Deferoxamine; Feasibility Studies; Fluorodeoxyglucose F1 | 2003 |
Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Cycle; Cell Division; Cell Line, Tumor; Chelati | 2004 |
Association of DNA-dependent protein kinase with hypoxia inducible factor-1 and its implication in resistance to anticancer drugs in hypoxic tumor cells.
Topics: Antibodies; Cell Hypoxia; Cell Line, Tumor; Deferoxamine; DNA Helicases; DNA-Activated Protein Kinas | 2004 |
Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Carbohydrate Sequen | 2005 |
Reversible inhibition of caspase-3 activity by iron(III): potential role in physiological control of apoptosis.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Deferoxamine; Enzyme Activation; Enzyme Inhibitors; Ferric | 2006 |
Paramagnetic pharmaceuticals for magnetic resonance imaging.
Topics: Abdomen; Adult; Animals; Brain; Contrast Media; Deferoxamine; Electron Spin Resonance Spectroscopy; | 1984 |
Deferoxamine mesylate enhancement of 67Ga tumor-to-blood ratios and tumor imaging.
Topics: Animals; Breast Neoplasms; Deferoxamine; Female; Gallium Radioisotopes; Hodgkin Disease; Humans; Lun | 1982 |
[Comparison between serum ferritin and induced sideruria in the diagnosis of disorders of iron metabolism].
Topics: Adult; Aged; Deferoxamine; Female; Ferritins; Humans; Inflammation; Iron; Male; Metabolic Diseases; | 1981 |
Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro.
Topics: Antibodies, Monoclonal; Breast Neoplasms; Deferoxamine; Down-Regulation; Female; Humans; Male; Neopl | 1995 |
Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice.
Topics: Animals; Antibodies, Monoclonal; Deferoxamine; Immunoconjugates; Isotope Labeling; Mice; Mice, Nude; | 1997 |
The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Topics: Antineoplastic Agents; Apoptosis; Benzaldehydes; Cell Cycle; Cell Division; Deferoxamine; DNA Fragme | 1997 |
Menadione-induced cell degeneration is related to lipid peroxidation in human cancer cells.
Topics: Calcium; Carcinoma, Hepatocellular; Cell Death; Chelating Agents; Deferoxamine; Dicumarol; Glutathio | 1998 |
Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis.
Topics: Adrenomedullin; Cell Hypoxia; Culture Media, Conditioned; Deferoxamine; DNA; DNA-Binding Proteins; G | 2000 |
Kinetic aspects of Ki-67 antigen expression in a normal cell line.
Topics: Blood; Cell Cycle; Cell Division; Cell Line; Cycloheximide; Deferoxamine; Embryo, Mammalian; G1 Phas | 1991 |
Control of heme internalization and metabolism in tumor cells: evidence for a heme-receptor?
Topics: Antibodies, Monoclonal; Cell Line; Deferoxamine; Heme; Hemin; Humans; Neoplasms; Receptors, Cell Sur | 1986 |
[Radioimmunodetection of a tumor with Ga-67 labeled antibodies: effect of radiolabeling on antibody activities].
Topics: Antibodies, Monoclonal; Deferoxamine; Gallium Radioisotopes; Humans; Isotope Labeling; Neoplasms; Ra | 1986 |
Mobilisation of iron by desferrioxamine in cases with low serum iron.
Topics: Anemia, Hypochromic; Bone Marrow Examination; Deferoxamine; Female; Hemoglobinuria; Humans; Injectio | 1969 |